Vasopressin as adjunctive therapy in pulmonary hypertension associated with refractory systemic hypotension in term newborns
Preprint
- 1 November 2022
- preprint
- Published by Springer Nature in Research Square
Abstract
Objective. The aim of our study is to describe the effects of vasopressin on term infants with persistent pulmonary hypertension under a standardized protocol. Study Design: In 2019, we designed a standardized protocol for the management of refractory hypotension in the context of pulmonary hypertension, which included the use of vasopressin. This is a retrospective cohort study to evaluate the clinical, laboratory, and echocardiographic outcomes of patients who required vasopressin in the context of this new protocol in a referral level IV neonatal intensive care unit. Results: We included 48 neonates with a median gestational age of 37 weeks in a period of 30 months (December 2019 to May 2022). Congenital diaphragmatic hernia was the main cause of persistent pulmonary hypertension in this cohort (82%). All patients were on mechanical ventilation and receiving inhaled nitric oxide. In our cohort at 4 hours after initiation of vasopressin, blood pressure, serum pH, and urinary output increased significantly. The vasoactive inotropic score, lactate and oxygenation index decreased. Echocardiographic follow-up also showed a decrease in the relative pressure of the right ventricle and an improvement in the cardiac output of both ventricles. There were no episodes of severe hyponatremia (<120 mmol/L). Discussion: This study showed that the use of vasopressin in neonates with persistent pulmonary hypertension and refractory systemic hypotension was associated with a rapid and significant improvement in oxygenation and hemodynamic markers of perfusion, including blood pressure. This association was early during the first hours of treatment and vasopressin was safely withdrawn after a median of 3 days of treatment.Keywords
All Related Versions
- Version 1, 2022-11-01, Research Square
- Published version: Journal of Perinatology, 44 (10), 1448.
This publication has 14 references indexed in Scilit:
- Vasopressin as a Rescue Therapy for Refractory Pulmonary Hypertension in NeonatesPediatric Critical Care Medicine, 2014
- Renal Vasodilatory Action of Arginine Vasopressin in Extremely Low Birth Weight InfantsThe Tohoku Journal of Experimental Medicine, 2013
- Vasopressin for Refractory Hypotension in Extremely Low Birth Weight InfantsThe Journal of Pediatrics, 2010
- Low‐dose vasopressin infusion therapy for refractory hypotension in ELBW infantsPediatrics International, 2010
- Treatment of Refractory Hypotension With Low-Dose Vasopressin in a Patient Receiving ClozapineJournal of Cardiothoracic and Vascular Anesthesia, 2010
- Vasopressin and its role in critical careContinuing Education in Anaesthesia Critical Care & Pain, 2008
- Risk Factors for Persistent Pulmonary Hypertension of the NewbornPediatrics, 2007
- Diagnostic criteria and therapeutic interventions for the hypotensive very low birth weight infantJournal of Perinatology, 2006
- Vasopressin to attenuate pulmonary hypertension and improve systemic blood pressure after correction of obstructed total anomalous pulmonary venous returnThe Journal of Thoracic and Cardiovascular Surgery, 2005
- Arginine Vasopressin Induces Endothelium-dependent Vasodilatation of the Pulmonary ArteryChest, 1993